Charles River Laboratories 

(Public, NYSE:CRL)   Watch this stock   
Find more results for CRL
Feb 9, 2010
International, Inc. Q4 2009 Earnings and 2010 Guidance Conference Call - Webcast
Feb 8, 2010
Q4 2009 International, Inc. Earnings Release
Jan 27, 2010
International, Inc. at Jefferies Global Healthcare Services Conference
Jan 13, 2010
International, Inc. at JPMorgan Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 11.27% -38.92%
Operating margin 14.94% -33.48%
EBITD margin - -26.69%
Return on average assets 6.19% -21.06%
Return on average equity 10.31% -34.14%
Employees 9,000 -

Address

251 Ballardvale Street
Wilmington, MA 01887
United States - Map
+1-978-6586000 (Phone)
+1-978-6587132 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Charles River Laboratories discussed on blogs

Charles River Laboratories discussions

  View all discussions »

Description

Charles River Laboratories International, Inc. (Charles River) is a global provider of solutions that advance the drug discovery and development process, including research models and associated services, and outsourced preclinical services. The Company operates in two segments: Research Models and Services (RMS) and Preclinical Services (PCS). The Company provides the animal research models required in research and development of drugs, devices and therapies. Charles River’s customer base includes global pharmaceutical companies, a range of biotechnology companies, as well as government agencies, hospitals and academic institutions worldwide. The Company operates approximately 70 facilities in 17 countries worldwide. During the fiscal year ended December 27, 2008 (fiscal 2008), the Company acquired NewLab BioQuality AG and MIR Preclinical Services.

Officers and directors

James C. Foster
Chairman of the Board, President, Chief Executive Officer
Age: 58
Bio & Compensation - Reuters
Thomas F. Ackerman
Chief Financial Officer, Corporate Executive Vice President
Age: 54
Bio & Compensation - Reuters
David P. Johst
Corporate Executive Vice President, Chief Administrative Officer
Age: 47
Bio & Compensation - Reuters
Christopher Berthoux
Corporate Executive Vice President - Global Sales and Marketing, Chief Commercial Officer
Age: 46
Bio & Compensation - Reuters
Real H. Renaud
Corporate Executive Vice President, President - Global Research Models and Services
Age: 62
Bio & Compensation - Reuters
Nancy A. Gillett Ph.D.
Corporate Executive Vice President, President - Global Preclinical Services
Age: 53
Bio & Compensation - Reuters
Stephen D. Chubb
Director
Age: 65
Bio & Compensation - Reuters
Douglas E. Rogers
Director
Age: 55
Bio & Compensation - Reuters
William H. Waltrip
Director
Age: 71
Bio & Compensation - Reuters
Samuel O. Thier M.D.
Director
Age: 71
Bio & Compensation - Reuters